Stable Isotope Utilization and Optimization

---

MS is a universal detector but the standard language of measurement method called 'calibration curve' is not well-suited for mission-critical MS testing. The MS is destined to become a routine clinical testing system but the current standard language does not yield consistent, clinically actionable results. Whenever it does, it is broadly agreed that the MS will be indispensable in healthcare. Future is now: QuantaPro has the platform to make this collective hope a reality! 

NOTE: The X-ray and MRI photos symbolically illustrate the dramatic difference between these MS languages.

There are many analytical challenges associated with calibration curve method based on serial dilutions and external standards for quantitation. For example, more than 20 different sources of error that can be produced in the lab are often not spotted and corrected for. These errors are additive and vary even from one test to same test done consequently. Producing clinically actionable results is a long, laborious and always a very difficult task.

Each molecule has an isotopic signature. By advancing a 60-year technology called Isotope Dilution, we optimized application of this signature in our testing method. One particular implementation called Thor's Hammer is a 2025 R&D-100 award winner. Our results exceed FDA standards for analytical quality. We don't need calibration curves because each measurement is inherently calibrated. The alphabet of the native language of the MS are the stable isotopes. The results are  instrument-to-instrument and lab-to-lab reproducible anywhere in the world. That will lead to data harmonization and greater global health outcomes.

The two pictures on this page illustratively demonstrates the difference between calibration curves (analogue) and SIO (digital). Just like the MRI, the SIO-enabled MS testing data provides the confidence and fidelity that is needed to see the analytical picture clearly whether it is for diagnosis or therapy monitoring. Our platform is also very valuable when it is used for companion diagnostic testing in drug development by shortening the biologic drug development resulting in huge savings. When biologic drugs reach the market faster, stratified patients win by selecting more effective, targeted therapeutic treatments.

SIO is an ideal MS tool for quantitative targeted-biomarker testing for one or more anlaytes in complex sample mixtures, such as blood, urine, etc. Our test assays also include secondary biomarkers within the  the proteomic data that are available after each MS test. The benefit is the additional confidence by the clinician in the results and clarity in diagnoses or assessing disease progression.

Recognized as the only method capable of producing legally defensible data, US EPA published in 2008, a benchmark environmental protocol based on our platform and continues to use it in its enforcement cases with 100% success in the courts. Now, supported with additional capabilities of the SIO-enabled platform QuantaPro is taking the MS to the clinic to address measurement need and fill the gaps in test delivery. Let us know how we can help with your testing needs; drop us a line.